Aside from limiting fibrosis and modulating the TME, TGF‐β inhibitors can also block lymphocyte depletion, drastically improving the efficacy of widely used adoptive cell antitumour therapies such as tumour‐infiltrating lymphocyte (TIL) therapy, engineered T cell receptor (TCR) therapy or chimeric antigen receptor (CAR) T cell therapy [59]. Here, TGFB1 is linked to neoplasm.